Absolute quantification of DcR3 and GDF15 from human serum by LC-ESI MS

Journal of Cellular and Molecular Medicine

Volumn 19, Issue 7, 2015, Pages 1656-1671

  Lancrajan, Ioana ^a   Schneider Stock, Regine ^a   Naschberger, Elisabeth ^b   Schellerer, Vera S ^b   Stürzl, Michael ^b   Enz, Ralf ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Absolute quantification; Biomarker; LC ESI MS; Low abundance proteins; Mass spectrometry; Partial denaturation; Proteomics; Serum

Indexed keywords

DECOY RECEPTOR 3; GROWTH DIFFERENTIATION FACTOR 15; BIOLOGICAL MARKER; GDF15 PROTEIN, HUMAN; MESSENGER RNA; PLASMA PROTEIN; TNFRSF6B PROTEIN, HUMAN;

ARTICLE; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL PERMEATION CHROMATOGRAPHY; HISTOPATHOLOGY; HUMAN; LIQUID CHROMATOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DENATURATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; AMINO ACID SEQUENCE; BLOOD; CHEMISTRY; GENETICS; IMMUNOPRECIPITATION; LIMIT OF DETECTION; METABOLISM; MOLECULAR GENETICS; PEPTIDE MAPPING; PROCEDURES; SIZE EXCLUSION CHROMATOGRAPHY;

AMINO ACID SEQUENCE; BIOMARKERS; BLOOD PROTEINS; CHROMATOGRAPHY, GEL; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; IMMUNOPRECIPITATION; LIMIT OF DETECTION; MOLECULAR SEQUENCE DATA; PEPTIDE MAPPING; PROTEIN DENATURATION; PROTEOLYSIS; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B; RNA, MESSENGER; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 84933059862     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12540     Document Type: Article

References (40)

1. Opstal-van Winden AWJ, Krop EJM, Karedal MH, et al. Searching for early breast cancer biomarkers by serum protein profiling of prediagnostic serum: a nested-case control study. BMC Cancer. 2011; 11: 381-92.
2. Ray S, Reddy PJ, Jain R, et al. Proteomic technologies for the identification of disease biomarkers in serum: advances and challenges ahead. Proteomics. 2011; 11: 2139-61.
3. Zolla L. Proteomics studies reveal important information on small molecule therapeutics: case study on plasma proteins. Drug Discov Today. 2008; 23-24: 1042-51.
4. van den Broek I, Niessen WM, van Dongen WD. Bioanalytical LC-MS/MS of protein-based biopharmaceuticals. J Chromatogr B Analyt Technol Biomed Life Sci. 2013; 929: 161-79.
5. Karpova MA, Moshkovskii SA, Toropygin IY, et al. Cancer -specific MALDI-TOF profiles of blood serum and plasma: biological meaning and perspectives. J Proteomics. 2010; 73: 537-51.
6. Righetti PG, Boschetti E, Lomas L, et al. Protein Equalizer Technology: the quest for a "democratic proteome". Proteomics. 2006; 6: 3980-92.
7. Au JS, Cho WC, Yip TT, et al. Deep proteome profiling of sera from never-smoked lung cancer patients. Biomed Pharmacother. 2007; 61: 570-7.
8. Bouamrani A, Hu Y, Tasciotti E, et al. Mesoporous silica chips for selective enrichment and stabilization of low molecular weight proteome. Proteomics. 2010; 10: 496-505.
9. Tan J, Zhao WJ, Yu JK, et al. Capture, enrichment, and mass spectrometric detection of low-molecular-weight biomarkers with nanoporous silicon microparticles. Adv Healthc Mater. 2012; 1: 742-50.
10. Bakun M, Karczmarski J, Poznanski J, et al. An integrated LC-ESI-MS platform for quantitation of serum peptide ladders. Application for colon carcinoma study. Proteomics Clin Appl. 2009; 3: 932-46.
11. Villanueva J, Shaffer DR, Philip J, et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest. 2006; 116: 271-84.
12. Tessitore A, Gaggiano A, Cicciarelli G, et al. Serum biomarkers identification by mass spectrometry in high-mortality tumor. Int J Proteomics. 2013; 125858. doi:10.1155/2013/125858.
13. Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem. 2001; 47: 624-30.
14. Simon I, Liu Y, Krall KL, et al. Evaluation of the novel serum markers B7-H4, Spondin 2, DcR3 for diagnosis and early detection of ovarian cancer. Gynecol Oncol. 2007; 106: 112-8.
15. Brown DA, Ward RL, Buckhaults P, et al. GDF15 serum level and genotype: association with Progress and prognosis of colorectal carcinoma. Clin Cancer Res. 2003; 9: 2642-50.
16. Kim HJ, Yu MH, Kim H, et al. Noninvasive molecular biomarkers for the detection of colorectal cancer. BMB Rep. 2008; 41: 685-92.
17. Fujimura Y, Miura D. MALDI mass spectrometry imaging for visualizing in situ metabolism of endogenous metabolites and dietary phytochemicals. Metabolites. 2014; 4: 319-46.
18. Huang MQ, Lin W, Wang W, et al. Quantitation of P450 3A4 endogenous biomarker - 4β-hydroxycholesterol - in human plasma using LC/ESI-MS/MS. Biomed Chromatogr. 2014; 28: 794-801.
19. Wilton JH, Titus MA, Efstathiou E, et al. Androgenic biomarker prof|ling in human matrices and cell culture samples using high throughput, electrospray tandem mass spectrometry. Prostate. 2014; 74: 722-31.
20. Zhang G, Annan RS, Carr SA, et al. Overview of Peptide and Protein Analysis by Mass Spectrometry. Curr Protoc Mol Biol. 2014; 108: 10.21.1-21.30.
21. Beynon RJ, Doherty MK, Pratt JM, et al. Multiplexed absolute quantification in proteomics using artificial QCAT proteins of concatenated signature peptides. Nat Methods. 2005; 2: 587-9.
22. Pratt JM, Simpson DM, Doherty MK, et al. Multiplexed absolute quantification for proteomics using concatenated signature peptides encoded by QconCAT genes. Nature Protocol. 2006; 1: 1029-43.
23. Mimeault M, Batra SK. Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer. J Cell Physiol. 2010; 224: 626-35.
24. Liang QL, Wang BR, Li GH. DcR3 and survivin are highly expressed in colorectal carcinoma and closely correlated to its clinicopathologic parameters. J Zhejiang Univ Sci B. 2009; 10: 675-82.
25. Nakamura T, Scorilas A, Stephan C, et al. Quantitative analysis of macrophage inhibitory cytokine-1 (GDF15) gene expression in human prostatic tissues. Br J Cancer. 2003; 88: 1101-4.
26. Koopmann J, Buckhaults P, Brown DA, et al. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res. 2004; 10: 2386-92.
27. de Wit NJ, Rijntjes J, Diepstra JH, et al. Analysis of differential gene expression in human melanocytic tumour lesions by custom made oligonucleotide arrays. Br J Cancer. 2005; 92: 2249-61.
28. Zhao L, Lee BY, Brown DA, et al. Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Res. 2009; 69: 7696-703.
29. Ge Z, Sanders AJ, Ye L, et al. Aberrant expression and function of death receptor-3 and death decoy receptor-3 in human cancer. Exp Ther Med. 2011; 2: 167-72.
30. Hsu MJ, Lin WW, Tsao WC, et al. Enhanced adhesion of monocytes via reverse signaling triggered by decoy receptor 3. Exp Cell Res. 2004; 292: 241-51.
31. Chang YC, Hsu TL, Lin HH, et al. Modulation of macrophage differentiation and activation by decoy receptor 3. J Leukoc Biol. 2004; 75: 486-94.
32. Wu Y, Han B, Sheng H, et al. Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients. J Int J Cancer. 2003; 105: 724-32.
33. Chen J, Zhang L, Kim S. Quantification and detection of DcR3, a decoy receptor in TNFR family. J Immunol Methods. 2004; 285: 63-70.
34. Brown DA, Lindmark F, Stattin P, et al. Macrophage inhibitory cytokine 1: a new prognostic marker in prostate cancer. Clin Cancer Res. 2009; 15: 6658-64.
35. Koopmann J, Rosenzweig CN, Zhang Z, et al. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res. 2006; 12: 442-6.
36. Baumann G. Growth hormone heterogeneity: genes, isohormones, variants, and binding proteins. Endocr Rev. 1991; 12: 424-49.
37. Chapman JD, Goodlett DR, Masselon CD. Multiplexed and data-independent tandem mass spectrometry for global proteome profiling. Mass Spectrom Rev. 2014; 33: 452-70.
38. Percy AJ, Chambers AG, Parker CE, et al. Absolute quantitation of proteins in human blood by multiplexed multiple reaction monitoring mass spectrometry. Methods Mol Biol. 2013; 1000: 167-89.
39. Kuhn E, Wu J, Karl J, et al. Quantification of C-reactive protein in serum of patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and 13C-labeled peptide standards. Proteomics. 2004; 4: 1175-86.
40. Schulze WX, Usadel B. Quantitation in mass-spectrometry-based proteomics. Annu Rev Plant Biol. 2010; 61: 491-516.